CARMEL, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Richard Bartram, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Tuesday, September 12th, 2023, at 11:30 a.m. Eastern Time and will host 1-on-1 investor meetings.
About MBX Biosciences
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide™ (PEP™) therapeutic candidates to help people with endocrine disorders live fuller and healthier lives. MBX is advancing a pipeline of PEPs for clinically validated targets designed to deliver superior pharmaceutical properties and overcome key limitations of native peptide therapeutics. MBX's pipeline includes its lead product candidate MBX 2109, currently in Phase 1 development for the treatment of hypoparathyroidism (HP), and MBX 1416, entering Phase 1 development for the treatment of post-bariatric hypoglycemia (PBH). The company is supported by leading life science investors including Frazier Life Sciences, New Enterprise Associates, Norwest Venture Partners, OrbiMed, RA Capital Management and Wellington Management. MBX is based in Carmel, Indiana. To learn more, please visit the company website at www.mbxbio.com and follow us on LinkedIn and Twitter.
Media Contact:
Ian Stone
Evoke Canale
ian.stone@evokegroup.com
619-849-5388
Investor Contact:
Irina Koffler
LifeSci Advisors
ikoffler@lifesciadvisors.com
917-734-7387
